Emmanouil Rampakakis: None declared, Angela Cesta: None declared, John Sampalis: None declared, Claire Bombardier Grant/research support from: Dr Bombardier reports sources of funding for Ontario Best Practice Research Initiative Research grants from Abbvie, Janssen, Amgen, Medexus, Merck, Pfizer, and Novartis outside of the submitted work. Consulting Agreements: Abbvie, Covance, Janssen, Merck, Pfizer, Sanofi and Novartis outside of the submitted work. Advisory Board Membership: Hospira, Sandzox, Merck, Pfizer and Novartis outside of the submitted work.

DOI: 10.1136/annrheumdis-2020-eular.1751

SAT0050 PREDICTION OF RESPONSE TO CERTOLIZUMAB PEGOL TREATMENT BY FUNCTIONAL MRI OF THE BRAIN: AN INTERNATIONAL, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (PRECEPRA)


1Friedrich-Alexander University (FAU) Erlangen-Nürnberg; 2University Erlangen-Nürnberg, Institute for Experimental Pharmacology, Bamberg, Germany; 3Goethe University Frankfurt, Rheumatology and Immunology, Frankfurt, Germany; 4Fraunhofer TMP Frankfurt am Main, Germany; 5Hospita da Universidade (SRHUC), Department Reumatologia, Coimbra, Portugal; 6Universität Leipzig, Medizinische Klinik III - Bereich Rheumatologie, Leipzig, Germany; 7Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany; 8Klinik für Rheumatologie der Helios Fachklinik, Vogelsang-Gommern, Germany; 9Charité - Universitätsmedizin Berlin, Dpt. of Rheumatology and Clinical Immunology, Berlin, Germany; 10Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Abteilung für Neuroradiologie, Erlangen, Germany; 11Belgrade University School of Medicine, Institute of Rheumatology, Belgrade, Serbia

Background: Personalization of RA treatment is not optimal due to lack of predictors. We previously demonstrated in RA patients that central nervous system (CNS) pain response to tender joint compression, measured by using functional MRI (fMRI) of the brain rapidly wanes after 24 hours of anti-TNF administration and that a higher pre-treatment BOLD signal volume seems to predict clinical response to treatment with certolizumab-pegol (CZP)1–4. We therefore hypothesized that the CNS pain response upon compression of a painful joint could predict subsequent anti-TNF treatment response.

Objectives: To compare disease activity after 12-weeks of CZP treatment to that of placebo in DMARD-refractory RA patients based on pre-treatment baseline CNS pain response measured using BOLD fMRI.

Methods: Adult RA patients fulfilling the 2010 ACR/EULAR classification criteria with a DAS28≥3.2 under stable DMARD treatment for at least 3 months were eligible. Patients underwent fMRI scanning of the brain at screening for stratification by CNS pain response. Whole brain BOLD-signal-voxel-count of 700 units classifying between low and high, and were randomized to CZP or placebo (5:1). The primary outcome was low disease activity (LDA, DAS28≤3.2) after 12 weeks of treatment.

Results: 156 RA patients, inadequate responders to csDMARD, signed the informed consent. 139 patients (46/47, 46/49 and 42/43) (99 females, 71%) with moderate-high disease activity (mean (SD) DAS28: 4.83 (1.03)) could be included respectively and completed the 12-week study treatment. Geometric mean (SD) numbers of baseline BOLD signal positive voxels were 559 (10), 81 (12) and 2498 (3) in the 3 arms respectively. The mean DAS28 (SD) scores after 12 weeks of study treatment were Placebo: 3.96 (1.06) and CZP-H: 3.06 (1.04). LDA was achieved in 12/47 patients (25.5 %) in placebo, 22/49 (44.9%) and 24/43 (56.8%) in the CZP-L and CZP-H arm. The linear effect term for the ordinal study group variable supported a linear trend of increasing CZP treatment effect with increasing baseline CNS pain response. RR (95% CI) for achieving LDA with each unit increase in treatment category over placebo was 1.79 (1.24 to 2.74, p=0.003).

Conclusion: A higher pre-treatment brain activity in response to pain measured with fMRI predicts the chance of achieving low disease activity with CZP treatment.

References:

Acknowledgements: The study was supported by an unrestricted grant from UCB Pharma (SPRIL, Belgium).

Disclosure of Interests: Jürgen Rech Consultant of: BMS, Celgene, Novartis, Roche, Chugai, Speakers bureau: AbbVie, Biogen, BMS, Celgene, MSD, Novartis, Roche, Chugai, Pfizer, Lilly, Koray Tasacari: None declared, Hannah Schenker: None declared, Marina Sergeyeva: None declared, Mageeshwar Selvakumar: None declared, Laura Konerth: None declared, Julia Prade: None declared, Sandra Strobelt: None declared, Melanie Hagen: None declared, Jutta Prade: None declared, Sandra Strobelt: None declared, Jutta Prade: None declared, Larissa Valor: None declared, Axel Hueber: Grant/research support from: Novartis, Lilly, Pfizer, EIT Health, EU-IMI, DFG, Universität Erlangen (EFI), Consultant of: AbbVie, BMS, Celgene, Gilead, GSK, Lilly, Novartis, Speakers bureau: GSK, Lilly, Novartis, David Simon Grant/research support from: Else Kröner-Memorial Scholarship, Novartis, Consultant of: Novartis, Lilly, Arnd Kleyer Consultant of: Lilly, Gilead, Novartis, Abbvie, Speakers bureau: Novartis, Lilly, Frank Behrens Grant/research support from: Abbvie, Pfizer, Roche, Chugai, Janssen, Consultant of: Abbvie, Pfizer, Roche, Chugai, UCB, BMS, Celgene, MSD, Novartis, Biotech, Janssen, Genzyme, Lilly; Boehringer; Sandzox, Speakers bureau: Abbvie, Pfizer, Roche, Chugai, UCB, BMS, Celgene, MSD, Novartis, Biotech, Janssen, Genzyme, Lilly; Boehringer; Sandzox, José Antonio P. da Silva Grant/research support from: Pfizer, Abbvie, Consultant of: Pfizer, AbbVie, Roche, Lilly, Novartis, Christoph Baerwald Consultant of: CGB received speaker or consulting fees from AbbVie, Paid instructor for: CGB received speaker or consulting fees from AbbVie, Speakers bureau: CGB received speaker or consulting fees from AbbVie, Stephanie Finzel: None declared, Reinhard Voll: None declared, Eugen Feist Consultant of: Novartis, Roche, Sobi, Lilly, Pfizer, Abbvie, MSD, Sanofi, Speakers bureau: Novartis, Roche, Sobi, Lilly, Pfizer, Abbvie, MSD, BMS, MSD, Sanofi, Arnd Doerfler: None declared, Nemanja Damjanov Grant/research support from: from AbbVie, Pfizer, Roche, Consultant of: AbbVie, Gideon Richter, Merck, Novartis, Pfizer, and Roche, Speakers bureau: AbbVie, Gideon Richter, Merck, Novartis, Pfizer, and Roche, Andreas Hess: None declared, Georg Schett: Speakers bureau: AbbVie, MS, BMS, Celgene, Janssen, Ei Lilly, Novartis, Roche and UCB

DOI: 10.1136/annrheumdis-2020-eular.4288

SAT0051 REMISSION IN RHEUMATOID ARTHRITIS PATIENTS: A CLUSTER ANALYSIS TO IDENTIFY AND CHARACTERIZE SUBPOPULATIONS OF PATIENTS

A. Madrid García1, D. Freites Nuñez2, J. Font2, I. Hernandez2, L. León2, J. I. Colomer2, I. González-Alvaro2, B. Fernandez2, J. A. Jover2, L. Abasolo2, L. Rodrigo Rodriguez2. 1Fundación para la Investigación Biomedica - HCSC, Madrid, Spain; 2Fundación para la Investigación Biomedica - HCSC, Rheumatology, Madrid, Spain; 3Hospital Clínico San Carlos, Rheumatology, Madrid, Spain; 4Hospital Universitario La Princesa, Madrid, Spain

Background: Disease Activity Score (DAS) is a continuous measure of Rheumatoid Arthritis (RA) activity, used in clinical practice for monitoring disease progression and for documenting treatment response. According to EULAR, the clinical desired target is to achieve a remission state (or failing that, low disease activity). However, the population of RA patients in this state could be heterogenous.

Methods: Adult patients with active RA were enrolled from 2015 to 2019, in Spain. Remission was defined as DAS ≤2.6. Clinical and biological data were collected every 12 months. A cluster analysis was performed using hierarchical, k-means and probabilistic approaches, with the aim to group patients in different clusters with different degrees of remission and to assess differences in those predictors of remission.

Results: 111 patients were included in this analysis. 79 (71%) of them achieved remission during the follow-up period, with a mean follow-up of 18 months. A hierarchical approach using Ward’s method was used. Four clusters were obtained. Cluster 1: 37 patients, 73% of them achieved remission. Cluster 2: 23 patients, 39% of them achieved remission. Cluster 3: 19 patients, 32% of them achieved remission. Cluster 4: 22 patients, 77% of them achieved remission. The cluster with the highest rate of remission was characterized by a lower age, a shorter duration of disease, lower CRP and ESR levels, and a higher rate of biological therapies.

Conclusion: A cluster analysis was performed to identify and characterize subpopulations of patients with rheumatoid arthritis who achieve remission. The results suggest that patients with lower age, shorter duration of disease, lower CRP and ESR levels, and higher rate of biological therapies achieve remission at a higher rate. Further studies are needed to validate these findings.

Acknowledgements: This study was supported by the FIS (PI18/02012) and the Fondo de Investigación Sanitaria (PI18/01813).